Oncothermia Journal
Volume 7



Download the full journal


Douwes FR (2013) Transurethral hyperthermia in prostate cancer: a ten year observation study. Oncothermia Journal 7:19-19

“Introduction Prostate cancer (Pca) is the most frequent cancer of men with approximately 31.500 new cases per year. The most important risk factor is age. Before age 50 clinically evident PCa are extremely rare and in most cases hereditary. More than 90% appears after age 60 and older. Between age 60 and 70 we expect that 50 of 100.000 men per year test positive for PCa and between age 75 and 85 approximately 400 men ….”


Meggyeshazi N, Andocs G, Spisak S, Krenacs T (2013) Early changes in protein expression releated to modulated electro-hyperthermia. Oncothermia Journal 7:21-22

“Background Modulated electro-hyperthermia (mEHT) is a widely used non-invasive technique for targeted tumor treatment [1-4]. The capacitive coupled modulated radiofrequency enriches in the tumor tissue (because of its dielectric differences [5]) without harming the sorrunding non-malignant tissues. Beside the temperature dependent effect mEHT causes in the tumor tissue, it has a non-temperature dependent tumor destruction effect, which is three times higher than the conventional hyperthermia with the temperature dependent outcome only [6]. Here our aim was to study early changes in protein expression either related or not to the temperature changes in tumors with a single shot of mEHT…..”


Acs B, Szasz O (2013) Oncothermia in practice: quality assurance, applications, devices. Oncothermia Journal 7:24-24

“Introduction Various kinds of hyperthermia devices are used in oncology, but the stable breakthrough of the applications has not been reached yet. Oncothermia offers strong scientific basis and good clinical practice as well. The very dynamic scientific and medical activity of Oncotherm is known in the scientific community through its many publications and accepted results. We are pioneering the electromagnetic treatments in oncology. The modulated electric field with RF carrier frequency of oncothermia is a leading method in oncologic hyperthermia by its treatment number all over the world. We are very active at all the international forums and conferences to make conditions risk-free and safe, ensure the patients of the safety of the treatment and your business also. The objective of this work is to show the oncothermia in practice and make sure the information about the actual safety regulations and certifications….”


Andocs G, Okamoto Y, Osaki T, Tsuka T, Imagawa T, Minami S, Balogh L, Meggyeshazi N, Szasz O (2013) Oncothermia research at preclinical level. Oncothermia Journal 7:26-32

“Background

Oncothermia method (OTM) has been applied in human oncology since 1989 [1]. Its clinical results excellently show the advantages of the method [2], however the details of its mechanism are being intersively investigated even now. Oncothermia research group conducts invetigations at all levels of scientific research, from in vitro studies to human clinical trials [3]. The tumor destruction efficacy and the role of temperature independent effects of the OTM were proven in vivo [4], but the complex electromagnetic paramters playing crucial role in achieving these antitumor effects have not yet exactly been determined. On the other hand in the veterinary oncology practice there is a huge need for an effective treatment to cure malignant diseases due to the increasing incidence of cancer in pet animals [5], and the lack of a really effective and relatively cheap method to cure. For these reasons, Oncotherm created a specialized research device for preclinical invetigations/veterinary clinical use, the VetEHY510 system, presented in Figure 1……”


Roussakow S (2013) Russian Oncothermia Manual. Oncothermia Journal 7:33-33

“Though oncothermia is becoming the world-leading hyperthermia technique, there is no clear, exact and unified rules of its clinical application. The approach stating oncothermia as an individualized treatment which is not possible to manage ‘in general’ makes oncothermia rather an art than a technology. Such an art is impossible to use widely in modern technological medicine. We developed a comprehensive but simple and clear ‘medical technology’ of oncothermia usage for Russian market named ‘Treatment of solid malignant tumors by oncothermia’. This technology is a stable basis for oncothermia use for any personnel, from nurse to artist-physician: it gives the exact and simple-to-use recommendations for the first and possibility of limitless creativity for the latter. It includes recommendations for all the tumor localizations and all the clinical regiments: chemo- and radiomodification, neoadjuvant, adjuvant and palliative treatment and rehabilitiation. The technology is approved by Russian Ministry of Health and is used in Russia since October 2011…..”


Okamoto Y, Andocs G, Osaki T, Tsuka T, Imagawa T, Minami S (2013) Clinical application of Oncothermia against the tumors developed in deep tissue in Veterinary medicine. Oncothermia Journal 7:34-34

“Surgery, radiation, and chemotherapy are main tumor therapy in veterinary field as well as human medicine. However, there are some cases which we cannot inhibit recurrence and metastasis, or control good QOL. In particular, almost tumors developed in the deep tissues like abdomen and thorax are recognized as poor prognosis. We applied Oncothermia against 10 tumors which developed in abdomen and thorax. Treatment was performed 3 times per a week and 6 times in total. At pre- and post-treatment, CT examination was performed and measured the size of tumor. In 4 out of 10 cases, low dose chemotherapy was combined. As result, there was complete remission in 2 cases, partial remission in 2 cases, steady condition in 4 cases, and progressionin 2 cases. In 4 cases with combination therapy, the tumor size was decreased in 2 cases and tumor disappeared in 2 cases. These results suggest that Oncothermia is effective to the tumors developed in deep tissue in veterinary field. In particular, it was found that combination of Oncothermia and low dose chemotherapy is more effective than Oncothermia alone…..”


Pang CLK (2013) Progress of research of hyperthermia integration with TCM in the treatment of cancer. Oncothermia Journal 7:36-42

“With the development of clinical oncotherapies, integrative treatments have generally been recognized by the Oncology Association. Hyperthermia has proven its effectiveness in the treatment of cancer which is different from surgery, radiotherapy, chemotherapy and biotherapy. Besides integration with the above therapies, using this with TCM is a unique approach. The progress of research of hyperthermia integration with TCM in treating cancer will be presented according to the following six aspects:….”


Szasz A (2013) “Quo vadis” oncologic hyperthermia? Oncothermia Journal 7:44-58

“Abstract Hyperthermia was the very first first oncotherapy in human medicine based directly on sacral and philosophical roots in ancient cultures. The discovery of electromagnetism gave new hopes a century ago, however until up to now it has been suffering from lack of wide applications. Oncological hyperthermia struggles with multiple technical and medical problems which are far from the complete solution. Technically the deepheating, the precise focusing, the technical control and repeatability are challenging. The missing medical explanation of the phenomena, the missing acceptable and measurable dose, and the contra-feedback of physiology mechanisms block its acceptance. Multiple, most promising results and studies are mixed together with some negatives and controversial consequences, causing huge fluctuations of its applications. There are positive and negative “believers” of the method, but the decisional facts are missing. A new way gives shape to the development: heating in nano-range, which could solve most of the open problems in oncological hyperthermia….”


Moss R (2013) War against cancer. Oncothermia Journal 7:59-59

“The author directs an information and consultation service for people with cancer and their famiilies. To better inform his clients and readers, he travels around the world in search of new or innovative treatments that are clinically available for patients willing to travel. This travel has taken him to Asia, Latin America, most EU contries as well as most regions of the US. In this presentation, he will review his findings in various states and countreis, highlighting the use of complementary and alternative medicine (CAM) in various societis. Some of the treatments to be discussed are chronomodulated chemotherapy, antineoplastons, Coley’s toxins, sonophotodynamic therapy, newcastle disease virus vaccine, dendritic vaccine, immune pheresis, etc. The emphasis in the talk will be on clinics he has found that are using hyperthermia, and in particular Oncothermia, as part of their practice…..”


Huilgol N, Gupta S, Tiwari M, Sridhar CR (2013) Report of the single institute experience in treating head and neck cancer with hyperthermia and radiation as well as chemo-radiation. Oncothermia Journal 7:60-60

“Cancer accounts for 8 percent of death in India. Nearly 200,000 patients of new head and neck cancers are diagnosed in India. The overall survival of head and neck cancer has remained stable over 45-47% depending on race, socio-economic background and country. Organ sparing surgical techniques, and organ preserving approaches in the management of head and neck cancer are routinely practiced even in India. Hyperthermia despite being useful has not been a routinely available modality. At ACRO – Advanced Centre for Radiation Oncology of Nanvati Hospital, Mumbai, India, patients are offered hyperthermia as an adjunct to chemo-radiation or radiotherapy alone in all Stage of II-IV head and neck cancers, excluding that of Nasopharynx…….”


Mitagravia N, Bicher J, Devdariani M, Davlianidze L, Nebieridze M, Momtselidze N (2013) Autoregulation of the brain temperature during whole body hyperthermia. Oncothermia Journal 7:62-68

“The aim of this study was revealing the temperature changes in rats brain tissue caused by whole body hyperthermia. Analysis of received results allow to conclude, that the brain has a highly secured system of temperature autoregulation against the exogenous temperature changes. The upper limit of this autoregulation (for rats, at least) is in the range 45 oC of environment. An important role in the normal functioning of the brain temperature autoregulation system belongs to Nitric Oxide the behavioral disorders, observed in animals after Whole Body Hyperhtermia (sure within the range of brain temperature autoregulation) is hardly associated with the canges in temperature of the Central Nervous System, but rather have to be mediated by impaired blood circulation and oxygen supply to the brain tissues, caused by the rapid deteriorationof the blood rheological properties…..”


Vujaskovic Z (2013) Clinical trials in breast and bladder cancer: Thermally enhanced chemosensitization and drug delivery. Oncothermia Journal 7:69-69

“Over the past decade, hyperthermia (HT) researchers have made cutting edge advances in HT augmented delivery of liposomal drugs. The performance characteristics of temperature sensitive liposomal formulations containing chemotherapeutic agents are far superior to other formulations largely because of the rapid release characteristic at temperatures between 40 and 42°C and a significant improvement in drug delivery. Several preclinical studies provided compelling rationale to initiate a number of clinical trials that will be presented. In a phase I trial of low temperature sensitive liposomal Doxorubicin (Thermodox) and HT for breast cancer patients with chestwall recurrence, toxicities have generally been those that are typical for doxorubicin and no dose limiting toxicities have been observed thus far….”


Douwes FR (2013) Local and whole body hyperthermia in chemoresistant ovarian cancer. Oncothermia Journal 7:70-70

“Introduction The prognosis for patients with advanced ovarian cancer remains bleak. 5-year survival in stage III is 5- 10%. Primary and acquired resistance of tumor cells to antineoplastic drugs is a major cause of the limited efficiency of chemotherapy. In our retrospective analysis we present the treatment results for patients with advanced ovarian cancer using whole body hyperthermia (WBH) in combination with a second line or palliative chemotherapy….”


Kleef R (2013) Application of transurethral prostate hyperthermia in benign and malign prostate hyperplasia and chronic prostatitis. Oncothermia Journal 7:71-71

“Benign and malign prostate hyperplasia and chronic prostatitis (CP) pose a constant challenge in urology due to the known limitations and risk of transurethral resection of the prostate gland and in the limitations of antibiotic therapy in CP. New treatment approaches therefore are warranted. The transurethral prostate hyperthermia has undergone enormous technological improvements in the last 20 years, particularly in the area of localized hyperthermia. Based on the current knowledge of radio frequencies and short waves the hyperthermia treatment of the prostate has proven to be a promising, effective and safe therapy option for treatment of prostate diseases. The first three year retrospective analysis will be presented…..”


Roussakow S (2013) Critical analysis of randomized trials on hyperthermia: dubious effect and multiple biases. Oncothermia Journal 7:73-99

“Abstract Hyperthermia in oncology still remains an experimental treatment with no realistic future in clinical cancer therapy, though declaration of the undisputed efficacy of hyperthermia is a common place in every hyperthermia paper. We’ve studied available randomized trials on hyperthermia from the position of ‘null hypothesis’ to confirm or refuse the efficacy and safety of clinical hyperthermia, taking into account also the possible biases. Unfortunately, the careful analysis of 14 randomized clinical trials doesn’t confirm a clinical benefit of hyperthermia independently of its type: superficial, deep of whole-body. We haven’t found any positive trial not affected with biases. With correction to distortions, there is no trial with obvious long-term positive effect of hyperthermia…”


Giammaria F, Dentico P, Turrisi G, Milandri C (2013) Phase II clinical study on relapsed malignant gliomastreated with electro-hyperthermia. Oncothermia Journal 7:100-100

“The purpose of this study was to evaluate the activity and toxicity of electro-hyperthermia (ET) on relapsed malignant glioma patients. Twenty four patients with histologically diagnosed malignant glioma entered the study. Sixteen patients had glioblastoma multiforme, four had anaplastic astrocytoma grade III and four had anaplastic oligodendroglioma. All patients were pre-treated with temozolamide-based chemotherapy and radiotherapy. Hyperthermia with short radiofrequency waves of 13.56 MHz was applied using a capacitive coupling technique keeping the skin surface at 20 degrees C. The applied power ranged between 40-150 Watts and the calculated average equivalent temperature in the tumours was above 40 degreees C for more than 90% of the treatment duration. Two complete remission and 4 partial remission were achieved, with a response rate of 25%. The median duration of response was 10 months (range 5-88). The median survival of the entire patient population was 9 months, with 25% survival rate at 2 year. ET appears to have effectiveness in adults with relapsed astrocytoma and malignant glioma…”


Bicher IH (2013) Hyperfractinated thermoradiotherapy (HTRT) is more effective and less invasive than radiation or chemoradiation in heatable cancers – a meta analysis. Oncothermia Journal 7:102-107

“Introduction It has been proven in malignant cancers, that in case of metastatic nodes in the head and neck region [1, 2, 3, 4, 5, 6] and in several other locations [8, 9, 10] hyperthermia potentiates radiation therapy. Due to these early findings, clinical applications were limited to recurrent advanced or metastatic cancers [11, 12, 13]. However, prospective randomized trials in the 1990’s demonstrated the effectiveness of thermoradiotherapy not only in superficial tumors but also when deeper structures were affected [14, 15], provided these tumors could be effectively heated….”


Brenner J (2013) Strategies for the cancer treatment with hyperthermia. Oncothermia Journal 7:108-108

“Abstract In the recent years many new cancer clinics are using hyperthermia for the treatment of cancer We treat patients by an empirical way: One hour each session, Every other day one month, two months, more? Alone or combining with other treatment methods. What are the best ways to use the hyperthermia?...”


Wehner H (2013) Whole body hyperthermia in water bath: technical-physical aspects and clinical experiences. Oncothermia Journal 7:109-109

“It is accepted that the increase in core body temperature above 41.5 ° C may help to destroy tumor cells. Life of cancer patients is particularly threatened by the metastasis. Therefore systemic treatments are preferred. The discussion of the last two decades showed that every tenth of temperature increase helps to improve the damage of cancer cell. Studies by Suvernev et al confirmed efficient reduction of viruses infected individuals at temperatures above 42.5° C. So close to the available methods and their predictive success one should verify the feasibility of a whole-body thermal therapy…”


Joan VJ, Marta GB, Eloi P, Mauel AdC (2013) Complete responses after hyperthermic ablation by ultrasound guided high intensity focused ultrasound (USgHIFU) plus cystemic chemotherapy (SC) for locally advanced pancreatic cancer. Oncothermia Journal 7:111-114

“Abstract We describe results in unresectable pancreatic tumors treated with USgHIFU hyperthermia ablation plus adjuvant chemotherapy. Materials and Methods: 32 cases of non resectable pancreatic tumors were treated from March 2010 to March 2012, and all of them underwent systemic chemotherapy. Clinical responses (thermical ablation achieved) were measured by image techniques. They were 23 Stage III cases and 9 Stage IV cases. Complications were also analyzed….”


Assogna M, Castigliani G, Coletta D, De Chicchis M, Gargano L, Mauro F, Gabrielli F, Pantaleoni G, Pigliucci GM (2013) Chemotherapy combined with regional hyperthermia in locally advanced unresectable pancreatic cancer: clinical and anthropological benefits. Oncothermia Journal 7:116-118

“Today the adenocarcinoma of the pancreas shows a significant increase of incidence, mainly in western countries. This tumor tends to affect mainly the male population, smokers and has a marked effect in proportion to the increase of age. Recent studies have shown a correlation between pancreatic cancer and diets high in animal fat and protein, and the role of coffee is discussed. The symptomatology is often delayed and is mostly characterized by obstructive icterus, in the case of localization in the head, and of pain for involvement of nerve fibers both in the retroperitoneal tumors of the head and body-tail. It frequently turns out to be the weight loss caused by maldigestion to reduced synthesis and transit of pancreatic enzymes….”


Schwartz L, Summa M, Steyaert JM, Vergne AG, Baronzio GF (2013) New cancer paradigm and new treatment: the example of METABLOC. Oncothermia Journal 7:120-125

“Abstract
Hyperthermia has long been known to interfere with the tumor metabolism. The goal of this presentation is to review the potential of metabolic therapy and to suggest that its combination with hyperthermia may be of interest.
Objective In a land mark article, John Bailar published in the “New England Journal of Medicine” in 1997 the article: Are we losing the war on cancer? We recently confirmed that is still the case. We obtained mortality from the World Health Organization time-series data of 20 countries over 45 years (1961-2005)….”


Baronzio GF, Kiselevsky M, Ballerini M, Cassuti V, Schwartz L, Freitas I, Fiorentini G, Parmar G (2013) Hypoxia, Immunity, Metabolism and Hyperthermia. Oncothermia Journal 7:127-131

“Keywords
Hypoxia, innate immunity, immune-suppression, glycolysis, tumor metabolism, hyperthermia.
Introduction The local inflammatory reaction is characterized by an initial increase in blood flow to the site of injury, by increased vascular permeability and by an ordered influx of different effector cells, recruited from the peripheral blood and bone marrow to the site of lesion (1) Another characteristic of the inflammatory reaction is the presence of hypoxia and its modulation of innate immunity (2)….”


Jing-hong L, Yu Ling X (2013) Electrochemical therapy of tumors. Oncothermia Journal 7:133-144

“Abstract Application of electric current for the tumor-destruction has a long time history. The theory of the direct galvanic current (galvano-therapy, GT) is worked out by B.Nordenstrom in the frame of biologically closed electric circuits (BCEC). Later GT was extended by chemical considerations (EChT) and starting with pioneering work of Professor Xin YouLing, a wide, intensive application had been developed in China. My objective is showing the principles and practice of the EChT treatment modality for multiple advanced lesions….”


Hegyi G, Jian L (2013) Low back pain – complex approach of treatment CAM modalities (acupuncture and other type of dry-needling, “Targeted RF non invasive physiotherapy” for low back pain). Oncothermia Journal 7:146-155

“Absract For at least 2,500 years, acupuncture has been an integral part of traditional Chinese Medicine. Recently more people have been diagnosed with chronic disease and many of them have been poorly treated with conventional therapies. Those patients frequently prefer other forms of complementary medical treatments. Based on the theory of homeostatic equilibrium being the basis of health, acupuncture focuses on restoring the homeostasis by manipulating the complementary and opposing elements of yin and yang. It is possible that by affecting afferent nerve signaling, acupuncture may influence the release of endogenous opioids to promote pain relief….”


Yimin L, Pang CLK, Tao Z, Qiaoer C, Jingsheng H, Caixia G (2013) Deep regional hyperthermia combined with Traditional Chinese Medicine in treating benign diseases in Clifford Hospital. Oncothermia Journal 7:157-165

“Abstract
Objective: To analyze the effect of Deep Regional Hyperthermia in combination with Traditional Chinese Medicine (TCM) in treating benign diseases in Clifford Hospital. Methods: We had 143 cases with chronic pelvic inflammatory disease, 36 cases with chronic prostatitis, 21 cases with prostatic hyperplasia, and 35 cases with chronic bronchitis, and we performed the treatments as planned. The following treatments were given: Radiofrequency (RF) hyperthermia, TCM, Acupuncture, Antibiotic therapy….”


Yong-sen J, Bing-sheng H, Ji-an L, Hegyi G (2013) Regulation of Tonglian decoction on cell cycle and signal pathway mediated with NF-kB in cell line MGC-803 of gastric carcinoma. Oncothermia Journal 7:167-169

“Abstract Gastric Cancer (GC) is one of the most critical diseases around the world. Population of its morbidity reaches 1,000,000 every year, among which 42% patients are in China. Thus, both the incidence and the mortality of GC are twice as much as the average level in the world. Clinical practitioners and basic researchers have been working on it for years, trying to find effective and long-acting therapeutic method focusing on GC. Till nowadays, no one can deny that radio-chemotherapy and operation have nonnegligible side effects. At the same time, national medicine is showing more and more predominance in treating GC. Chinese herbs have been applied in China for thousands of years….”


Wei Q, Yasunori A, Andocs G, Gulbostan Y, Xin H, Aki KA, Isamu H, Yuka I, Naoki A, Hisahiro M (2013) A novel dendritic cell therapy with oncothermotherapy mediated by abscopal effect. Oncothermia Journal 7:170-170

“Objective
The abscopal effect on the tumor is a distant antitumor activity induced by local treatments. The study was to observe the induction of abscopal effect by the combination of dendritic cell therapy with oncothermia therapy.
Methods SCCVII (mouse squamous cell carcinoma) cells were injected into C3H/He mice at two separate sites, defined as a “primary” site that was treated and a “secondary” site outside the field of treatments…”


Wey S (2013) Infrared WBH for relapse prevention in cancer. Oncothermia Journal 7:171-171

“Whole body hyperthermia plays an important role in the concept of biological cancer therapy, mostly in palliative situations. In the adjuvant setting, there has only been casuistic data until now. The talk shows the immunology during / after chemotherapy and provides an overview of the immunological significance of fever, which most cancer patients have not experienced for many years before the disease. Since the opening of the praxis in early 2002, a collective of now > 60 patients (mainly breast cancer) has been observed. These patients were adjuvant treated with at least two whole body hyperthermia treatments. The follow-up so far shows a high number of patients with tumor-free survival even in high-risk constellation. The tumor after treatment should follow and evaluate this approach to a greater extend.”


Thaller A (2013) Treatment of a High Grade Glioma (GBM) with four different oncolytic viruses (Parvo HI, VSV, NDV-Nothabene and Sindbis-Virus), elected by the symptoms, delivered via an Intra-arterial Port-a-Cath-System and controlled by repeated MRIs. Oncothermia Journal 7:173-176

“Summary This is the first case report using different viruses to attack one tumour. They were chosen by the very unique method of human medicine: The patient, i.e. the highest authority, was asked to observe the development of the most conspicuous tumour associated symptoms in the course of therapy. The tumour was located in the gyrus cinguli on the right side of the frontal lobe, depressing the right ventricle and causing weakness of the left arm and leg. At the beginning of treatment the degree of these symptoms was estimated as 100%. Improvement was noted by a number below one and worsening by a number above 100%...”


Zais O, Szasz A (2013) Lyme disease and oncothermia. Oncothermia Journal 7:178-180

“Abstract Lyme-Disease is a tick-borne disease with multiple organ failure and systemic disorder. Dramatic change becomes apparent in the chronic phase of the disease. Chronic fatigue syndrome, lapse of concentration, depression, joint pain, muscle pain are a few, but major clinical symptoms characterizing the disease. The human immune-system is defenseless. Borrelia uses various mechanisms to escape from immuno-attacks or antibiotic therapies. This „stealth phenomenon“ needs new therapeutic principles to be interrupted. Our objective in this paper is to study the effect of oncothermia, which is a well-established oncological therapy, in Lyme disease. First, in our present work, we definitely concentrate on the quality of life of the patients….”


Ballerini M, Baronzio GH, Capito G, Szasz O, Cassuti V (2013) AndroTherm application for “La Peyronie” disease. Oncothermia Journal 7:182-188

“Peyronie’s disease is characterized by a scarring fribrosis within the tunica albugina of the penis that could lead to penile length loss, narrowing, curvature, erectile dysfunction, pain with erection.
Prevalence La Peyronie disease ( Induratio penis plastic ), is a developmental condition with acquired fibrotic changes and development of a fibrous plaque (fibrous inelastic scar) on the tunica albuginea of the penis. The Peyronie disease is mostly observable at the men of their middle ages ( 50-60 years ) in Caucasian race (1). The prevalence, commonly reported, is about 3-9% (2), but according to the autopsy statistics the disease would be present in more than 20% of men (3)….”


Roussakow S (2013) Where, when and why hyperthermia went wrong way? Oncothermia Journal 7:190-231

“‘Hyperthermia is generally regarded as an experimental treatment with no realistic future in clinical cancer therapy’ – Horsman and Overgaard said in 2007, though, trying to combat this statement. It’s difficult to find another method in medicine which remains experimental after 40 years of research and application. Hyperthermic community usually claims to technical problems of heating and heating control to justify this failure. To our mind, the problem is the ‘temperature concept’ of hyperthermia. Electromagnetic hyperthermia was finally derived from electromagnetic therapy near 1935, after 30-year fight between thermal and non-thermal concepts of electromagnetic fields application….”


Szasz O (2013) Essentials of Oncothermia. Oncothermia Journal 7:233-251

“Abstract Oncothermia is a method of hyperthermia in oncology, controlling the locally applied deep-heat by selectively targeting the cellular membrane of the malignant cells. The selection of the method is based on various biophysical and biochemical achievements. There are various differences between the malignant and healthy cells, which could be used for their selection by heat targeting. The primary selection factor is a different metabolic activity which creates distinguishable environments of the malignant cells. The other factor is the clear difference of dielectric properties of the membrane and near membrane extracellular electrolytes, marking off the malignancies….”


Szasz O (2013) Burden of oncothermia – Why is it special? Oncothermia Journal 7:253-258

“Abstract
There are many contradictory opinions about conventional hyperthermia in oncology. The main points are the physical, technical imperfection of classical heating, as well as the limits of the natural physiological feedback of the organism. We would like to present the definitive differences between oncothermia conventional hyperthermia, explaining the new line of problem-solving in this important field of oncology. Keywords: hyperthermia, oncothermia, nanotheremia, non-equilibrium, modulation….”


Youngsuk L (2013) Oncothermia application for various malignant diseases. Oncothermia Journal 7:260-265

“Abstract Oncothermia was introduced to our hospital in 2010. Our objective is to report results of 277 patients treated by oncothermia during 20 months. We present some characteristic cases and statistical study of the overall results. We concluded state the feasibility of oncothermia to treat high variety of malignant diseases also in their very advanced (T4N3M1) stages….”


Tae SJ, Sun YM, Jeasang Y, Sangwook L (2013) Cases that respond to Oncothermia monotherapy. Oncothermia Journal 7:267-277

“Abstract
There is a long history of hyperthermia in oncology, but its wide range acceptance and application is missing even today. A new approach of oncological hyperthermia, oncothermia, looks promising modality of the complementary treatment of advanced malignant cases. Our present article is targeting this method, trying to answer on the question of its feasibility to treat various advanced cases in monotherapy process, as well as its applicability for a long, large number of treatment sessions protocols….”


Fiorentini G, Yoon SM, Yan O, Andocs G, Baronzio GF, Laurent S, Balogh L, Szasz A (2013) Abscopal effect: new perspectives in Oncothermia. Oncothermia Journal 7:279-281

“Abstract Radiotherapy has a relevant action on the tumor environment and its distant component. Abscopal effect is the bystander effect of radiotherapy observed at a site distant to the irradiated one within the same patient. Abscoopal effect even though described, is not a common clinical event. We are reporting a documented observation of an abscopal effect in one patient with lung cancer treated on target with radiotherapy and oncotehrmia. This is the first case in literature of abscopal effects in lung cancer, a synergistic action between radiotherapy and oncotheramia is suggested…”


Kovago Cs, Meggyeshazi N, Andocs G, Szasz A (2013) Report of the pilot-study done for the proposed investigation on the possible synergic effect between high dose ascorbic acid application and oncothermia treatment. Oncothermia Journal 7:283-284

Abstract According to recent investigations, the parenteral application of ascorbic acid (vitamin C) at high doses has significant antitumor activity in in vitro assays. This fact is a very important using ascorbic acid as complementary drug with standard antitumoral therapy or in cases where currently no other potent treatment is possible. Although the specific method of action is still unclear: high concentration of ascorbic acid produces oxidative shock by H2O2 lethal for tumor cells beyond a certain level, however healthy cells can survive the same stress effect….”


Meggyehazi N, Andocs G, Krenacs T (2013) Programmed cell death induced by modulated electro-hyperthermia. Oncothermia Journal 7:286-287

“Abstract
Background: Modulated electro-hyperthermia (mEHT) is a non-invasive technique for targeted tumor treatment.
Method: HT29 human colorectal carcinoma cell line xenografted to both femoral regions of BalbC/nu/nu mice treated with a single shot OTM treatment. Histomorphologic, and immunhistochemical analysis TUNEL assay and R&D Apoptosis array were performed on tissue samples…”


Pesti L, Dankovics Zs, Lorencz P, Csejtei A (2013) Treatment of advanced cervical cancer with complex chemoradio – hyperthermia. Oncothermia Journal 7:289-291

“Abstract This single arm, retrospective, single institution study investigated intention to treat patients (n=72) with advanced cancer of cervix of uterus. The study was performed in 2001-2010; providing 331 sessions. All patients had radiotherapies as fractional radiotherapy and intracavital brachytherapy. Some patients (n=34) received chemotherapy (Cisplatin 40 mg/m2/week; concomitantly with teleradiotherapy) as well. Complementary to the tele-radiotherapy, oncothermia was used two times a week, targeting the pelvis. Applied energy dose was 45 W, 60 min…”


Lorencz P, Csejtei A (2013) Experience in the treatment of liver metastases with special reference to the consequences of interruption of long-run treatments. Oncothermia Journal 7:293-294

“Abstract Approximately 800 metastatic liver cases were treated with oncothermia in our department. Many of them had long-time, cumulatively, huge number of treatments handled the disease a chronic for years. We investigated the long-time effects of the treatments, together with them interruption of the treatment serial for a few weeks. We are reporting a typical case: mammary carcinoma with liver metastases. The metastatic lesion was treated for four years, but the termination of the treatment for two months was fatal at the end….”


Andocs G, Okamoto Y, Kawamotot, Osaki T, Tsuka T, Imagawa T, Minami S, Balogh L, Meggyeshazi N, Szasz O (2013) Oncothermia basic research at in vivo level. The first results in Japan. Oncothermia Journal 7:296-300

“Background
Oncothermia method (OTM) is a long time (since 1989) applied method in oncology [1] with great clinical success.[2] Oncothermia research group conducts investigations to reveal the basic mechanism of action of this tumor treatment method in basic research level performing a huge number of in vivo studies. The tumor destruction efficacy and the role of temperature independent effects of the OTM were proven earlier and presented elsewhere [3], [4], as well as the recent in vivo results [5], [6]. In this paper we summarize the first results we have achieved in Tottori University, Japan….”


Coletta D, Gargano L, Assogna M, Castigliani G, De Chicchis M, Gabrielli F, Mauro F, Pantaleoni G, Pigliucci GM (2013) Stabilization of metastatic breast cancer with capacitive hyperthermia plus standard-dose chemotherapy and/or metronomic. Oncothermia Journal 7:302-304

“Introduction
Worldwide, breast cancer accounts for 22.9% of all cancers (excluding non-melanoma skin cancer) in women and it is more than 100 times more common in women than in men, although men tend to have poorer outcomes due to delays in diagnosis. Prognosis and survival rates for breast cancer vary greatly depending on the cancer type, stage, treatment and geographical location of the patient. Survival rates in the western world are high, in developing countries, however they are much poorer….”


Strauss CA, Kotzen JA, Baeyens A, Mare I (2013) Oncothermia in HIV positive and negative locally advanced cervical cancer patients in South Africa. Oncothermia Journal 7:306-308

“Abstract
Aim: Investigate the clinical, economic and cellular effects of the addition of oncothermia to standard treatment for HIV positive and negative locally advanced cervical cancer patients in public healthcare in South Africa. Objectives: Evaluate the effect that the addition of oncothermia has on local disease control, progression free survival, overall survival at2 years, treatment toxicity, quality of life, economic impact and HIV status of participants. Radiobiology investigations will evaluate thermo-radiosensitivity and the molecular markers for thermo-radiosensitivity….”


Szasz O, Andocs G, Meggyeshazi N, Szasz A (2013) Oncothermia as personalized treatment option. Oncothermia Journal 7:310-316

“Abstract Oncothermia is a nanoheating technology personalized for individual status depending on the state, stage, grade, and other personal factors. The guiding line of the treatment keeps the homeostatic control as much effective as possible. One of the crucial points is the surface heat-regulation, which has to be carefully done by the electrode systems. The applied step-up heating supports the physiological selection. Recognizing the hysteresis type of SAR-temperature development the protocol could be well conducted….”


Nagy G, Meggyeshazi N, Szasz O (2013) Deep temperature measurements in oncothermia processes. Oncothermia Journal 7:318-321

“Abstract
Temperature in depth of in various model-systems was measured, starting with muscle and other phantoms. Temperature was measured by flouroptical system (Luxtron) in the various points of the phantoms. It was shown that the temperature can be selectively increased in the target. In water-protein phantom the protein coagulation (>60 °C) was observed selectively while the water temperature around it was a little higher than the room temperature….”


Szasz O, Andocs G, Meggyeshazi N, Szasz A (2013) Modulation effect in oncothermia. Oncothermia Journal 7:324-327

Abstract
Conventional hyperthermia is based on the local or systemic heating, which is measured by the realized temperature in the process. Oncothermia applies nano-heating, which means high energy absorption in nanoscopic range of the malignant cell-membrane selectively. This high temperature and its consequent stress create special effects: it evolves possibility of chaperone proteins to be expressed on the outer membrane by softening the membrane, and starts various excitations for programmed cell-death of the targeted malignant cell….”


Hegyi G (2013) Synergy between TCM and Oncothermia. Oncothermia Journal 7:329-332

“TCM and cancer
Traditional Chinese medicine-based herbal medicines have gained increasing acceptance worldwide in recent years and are being pursued by pharmaceutical companies as rich resources for newer drug discovery. For many years, traditional Chinese medicines (TCM) have been applied for the treatment of cancers in China and beyond. Chinese medicine employed treatments for cancer for over two millennia. The book The Rites of the Zhou Dynasty (1100- 400 BCE) refers to physicians specializing in the treatment of swellings and ulcerations or necrosis and ulcerations….”


Gallne-Valyi A (2013) Introduction of the international quality management systems by sample of Oncotherm Group. Oncothermia Journal 7:333-333

“Method: I would like to introduce the organizational structure and processes of Oncotherm Group and the requirements which should be adapted (see above). The Oncotherm Group consists of two parts: the Oncotherm Kft., which is in Hungary and the Oncotherm GmbH, which is in Germany, but these two firms are one unity. They are working together and they have got common quality management systems….”


Skrihar G (2013) Production support by LabView-based data-acquisition systems. Oncothermia Journal 7:335-336

“Abstract Medical devices are complex products requesting high level of safety and reliability because of their sophisticated functions. Automation of the quality control and the visualization of the steps of the production processes are useful supports of the production process. Our objective is to show a way of production support by LabView system….”


Szigeti GYP, Hegyi G, Szasz O (2013) Hyperthermia versus Oncothermia: cellular effects in cancer therapy. Oncothermia Journal 7:338-341

“Absract
Hyperthermia means overheating of the living object completely or partly. The fact the hyperthermia is not generally accepted as conventional therapy. The problem is its controversial performance. The controversy is originated from the complications of the deep heating and the focusing of the heat-effect. The idea of oncothermia solves the selective deep action on nearly cellular resolution. We would like to demonstrate the perspectives of oncothermia, as a highly specialized hyperthermia in clinical oncology. Our aim is to prove the ability of oncothermia to be a candidate to become a widely accepted modality of the standard cancer-care…."


Andocs G, Meggyeshazi N, Okamoto Y, Balogh L, Szasz A (2013) Bystander effect of oncothermia. Oncothermia Journal 7:343-347

“Background
Oncothermia (OTM) is an electro-hyperthermia modality, a long time (since 1989) applied method, [1],used successfully in human oncology [2]. OTM changes the paradigm of hyperthermia by targeted microscopic heat-liberation at the membrane of the malignant cells. This method creates inhomogeneous heating, and the microscopic temperature greatly differs far from the thermal equilibrium. The tumor destruction efficacy and the role of temperature independent effects of the OTM were proven earlier by a laboratory research, and were presented elsewhere [3], [4]….”


Lee DY, Haam SJ, Kim TH, Ihm JY, Kim EJ, Kim NY (2013) Oncothermia with chemotherapy in the patients with small cell lung cancer. Oncothermia Journal 7:349-356

“Abstract
Small cell lung cancer constitutes approximately 13% of all lung cancer types & SCLC is one of the most aggressive and lethal forms of lung cancer. And so chemotherapy including radiotherapy would be standard for SCLC, but it has very poor median survival of less than 4 months. This is why another form
of additional treatment to chemotherapy would be necessary and so oncothermia will be one of the additive treatment for prolonged survival time. We made a 6 year-long study of 31 patients with small cell lung cancer at the department of Thoracic & Cardiovascular surgery Gangnam…”



Posters


Fiorentini G, Milandri C, Dentico P, Giordani P, Catalano V, Burnkeila F (2013) Deep electro-hyperthermia with radiofrequencies combined with thermo-active drugs in patients with liver metastases from colorectal cancer (CRC): A phase II clinical study. Oncothermia Journal 7:35-358

Purpose

  • increase palliation  in patients with liver metastases from CRC
evaluate capacitavely coupled low-frequency 13.56 MHz deep hyperthermia cmbined with thermo-active drugs …”


Gramaglia A, Parmar G, Ballerini M, Cassuti V, Baronzio GF (2013) Liposomiated doxarubycyn (LD) and hyperthermia on glioblastoma relapsing after surgery, radiotherapy and two chemotherapy lines: a case report. Oncothermia Journal 7:359-359

“Rationale for using liposomal doxorubicin
Temozolomide is an imido-tetrazine readily absorbed orally and able to cross the blood brain barrier. TMZ has demonstrated activity against Glioblastoma and astrocytoma n various degrees, and in brain metastases (Reardon DA 2006, Addeo R 2011)….”


Kovago Cs, Meggyeshazi N, Andocs G, Szasz A (2013) Proposed investigation on the possible synergic effect between high dose ascorbic acid application and oncothermia treatment. Oncothermia Journal 7:360-360

Introduction
According to recent investigations, the parenteral application of ascorbic acid (vitamin C) at high doses has significant antitumor activity in vitro assays. This fact is a very important using ascorbic acid as complementary drug with standard antitumoral therapy or in cases here currently no other potent treatment is possible. Although the specific method of action is still unclear: high concentration of ascorbic acid produces oxidative shock by H2O2 lethal for tumor cells beyond a certain level, however healthy cells can survive the same stress effect….”


Meggyeshazi N, Andocs G, Krenacs T (2013) Programmed cell death induced by modulated electro-hyperthermia. Oncothermia Journal 7:361-361

Background
Modulated electro-hyperthermia (mEHT) is a non-invasive technique for targeted tumor treatment. The mEHT generated capacitive coupled modulated radiofrequency selectively accumulates in the tumor tissue without major effect in the surrounding normal tissues….”


Pesti L, Dankovics Zs, Lorencz P, Csejtei A (2013) Complex treatment of advanced uterine cervix Chemo-radio-thermotherapy case report. Oncothermia Journal 7:362-362

“Among malignant gynecologic diseases the morbidity of the squamous cell, planocellular carcinoma of uterine-cervix is 1300-1400 cases yearly, with mortality of 500 cases yearly in Hungary [approx. 10 million inhabitants]….”


Lorencz P, Csejtei A (2013) Experience in the treatment of liver metastases, with special reference to the consequences of interruption of long-run treatments. Oncothermia Journal 7:363-363

Introduction
Our department has been dealing with oncothermia since 2001. It is used as one of the complementary treatments which are applied together with the gold-standards. We had treated more than thousand patients with this modality. 80% of the treated patients had primer or metastatic malignant liver tumors. We are intensively studying the long-term application of the hyperthermia, transforming the treatment of malignancy to the same as for one of the chronic-diseases. The cohort which we had chosen received more than 60 oncothermia treatments, e are studying not only the long-time effects, but the response of long interruption (at least two weeks) of the treatment….”


Andocs G, Okamoto Y, Osaki T, Tsuka T, Imagawa T, Minami S, Balogh L, Meggyeshazi N, Szasz O (2013) Oncothermia basic research at in vivo level. The first results in Japan. Oncothermia Journal 7:364-364

Background
Oncothermia method (OTM) is a long time (since 1989) applied method in oncology, [1] with great clinical success. [2] Oncothermia research group conducts investigations to reveal the basic mechanism of action of this tumor treatment method in basic research level performing a huge number of in vivo studies. The tumor destruction efficacy and the role of temperature independent effects of the OTM was proven earlier and presented elsewhere [3], [4], as well as the recent in vivo results [5], [6]. In this presentation we summarize the first results we have achieved in Tottori University, Japan….”


Coletta D, Gargano L, Assogna M, Castigliani G, De Chicchis M, Gabrielli F, Mauro F, Pantaleoni G, Pigliucci GM (2013) Stabilization of metastatic breast cancer with capacitive hyperthermia plus standard-dose chemotherapy and/or metronomic. Oncothermia Journal 7:365-365

Introduction
In our long experience in Universitary Hyperthermia treatment of tumors associated with chemotherapy, we observed that response to associated treatment determines the disease stabilization and significant clinical benefit for 24 months in 12 cases of metastatic breast cancer,  whereas chemotherapy alone had shown ineffective with disease progression, bone marrow toxicity G3-4, fatigue G2-3, nausea and vomiting G1-G2, bone pain G3-4 and visceral pain G2-3. (Table 1)….”


Roussakow S (2013) Critical analysis of randomized trials on electromagnetic hyperthermia: doubtful effect and multiple biases. Oncothermia Journal 7:366-366

Introduction
Hyperthermia in oncology had been extensively studied since 60th. Despite of more than 13.000 publications, 50 monographs and manuals and more than 1200 clinical trials, hyperthermia is still not accepted as a regular cancer treatment. The current trial was performed for further eexplanation of this situation….”


Strauss CA, Kotzen JA, Baeyens A, Mare I (2013) Oncothermia in HIV positive and negative locally advanced cervical cancer patients in South Africa. Oncothermia Journal 7:367-367

Introduction
The investigation of technologies which can increase cancer treatment efficacy is driven by:

  • The high prevalence of Human Immunodeficiency Virus (HIV) and cervical cancer in South Africa1,2
  • The growing concerns that HIV infection and certain Antiretroviral Therapies (ARTs) increase the sensitivity to radiation therapy (RT) and chemotherapy,3,4,5
  • The economic impact of cancer on the already over-burdened healthcare system and economy in Afric6….”


Jückstock J, Eberhardt B, Kirchner H, Müller L, Sommer H (2013) Locoregional hyperthermia combined with chemotherapy for metastatic breast cancer patients – preliminary results of the Mammatherm-trial. Oncothermia Journal 7:368-368

Background
Treatment options for patients with metastatic breast cancer should be as effective and preferably as little toxic as possible. To date there is no standard therapy available and treatment regiments for metastatic breast cancer vary largely. Locoregional hyperthermia might show additive effects to chemotherapy due to an increased perfusion and a simultaneous occurrence of interstitial acidosis in tumor tissue. In randomized clinical trials the addition of hyperthermia to radiation in advanced breast cancer was associated with improved outcome. To our knowledge so far there are no randomized clinical trials evaluating the effect of a combination of hyperthermia and chemotherapy in beast cancer patients….”


Szasz O, Andocs G, Meggyeshazi N, Szasz A (2013) Oncothermia – personalized treatment option. Oncothermia Journal 7:369-369

Objective
The personalization of the oncological treatments is the new trend in modern medicine [1]. Oncothermia is a personalized treatment by tuned energy delivery to the targeted tumor [2].  This energy is well focused on cellular level [3], and makes the dose of energy optimal for cell destruction [4]. The personal feedback of the patient together with the natural homeostatic control of the treatment actions makes the treatment realistically personalized [5]…”


Nagy G, Szasz O, Andocs G, Meggyeshazi N, Szasz A (2013) Deep temperature measurements in oncothermia processes. Oncothermia Journal 7:370-370

Introduction
The controlled and focused heat-delivery to deep-seated tissues is a long-standing problem of the local hyperthermia in oncology, [1]. The multiple artificial methods to focus the temperature has numerous technical and physiological problems. The energy could be focused in planned accurate way, but the temperature is naturally spread, as well as the physiological controls likely contra-effects the actual heating process. Our objective is to show how oncothermia makes the energy delivery in controlled way in depth….”


Szasz O, Andocs G, Meggyeshazi N, Szasz A (2013) Oncothermia paradigm. Oncothermia Journal 7:371-371

Objective
Oncothermia is a new type of cancer treatment targeting the malignant cells on nano-range, at its membrane and exciting basic cellular signaling pathways, [1].  The front-line achievements enplaning the cellular differences between malignant and healthy cells were not used for selection in practical applications. Our objective is to show how oncothermia uses these brilliant and strongly proven results….”


Szasz O, Andocs G, Meggyeshazi N, Szasz A (2013) Modulation effect in oncothermia. Oncothermia Journal 7:372-372

Objective
One of the most special and distinguished effect of oncothermia is the modulation. This special effect is important for selection and apoptotic action of oncothermia, applied on basic of multiple patents, [1], [2], [3]. The applied amplitude modulated signal is of course not simple. Presently the amplitude modulated electromagnetic applications have their renewing in the professional literature [Szasz et al Oncothermia, Springer, 2010]. Our objective is to show the oncothermia modulation which is a new way of the modulation technique….”


Hegyi G, Szasz O, Szasz A (2013) Synergy of oncothermia and traditional Chinese medicine. Oncothermia Journal 7:373-373

“Introduction – Objective
Hyperthermia is the very first oncological treatment [1], started probable on sacral basis. Later Hippocrates described it using physiological process, but surprisingly the other ancient medical approach, the traditional Chinese medicine (TCM, [2]) had not been combined by this method. Probable the philosophical approach was different. Hyperthermia applied constrain force to overheat the body or a part of it, forcing reaction from the system (physiologic changes like blood-perfusion, immune changes, pH or other environmental changes, etc.), and use this anyway unusual reaction for heating….”


Gallne-Vagyi A (2013) Introduction of the international quality management system: Oncotherm Group. Oncothermia Journal 7:374-374

“OncoTherm Group
Common Quality Management System based on:

  • ISO 9001:2008 Quality Management System, Requirements
  • ISO 13485:20003/AC:2009 Medical Devices Quality Management Systems. Requirements for regulatory purposes
  • 93/42 EEC Medical Device Directive (MDD)…”


Szasz O, Szasz A (2013) Essence of Oncothermia. Oncothermia Journal 7:375-375

What are the limits of the old hyperthermia approach?
New paradigm is necessary for oncology
Hyperthermia contradiction:
“The biology is with us while the physics is against us” (J. Overgard)
Oncothermia changes the paradigm:
“The biophysics is with us”…”


Skrihar G (2013) Production support by LabView-based data-acquisition systems. Oncothermia Journal 7:376-376

The necessity of integrated data-acquisition systems
During the production of a product a lot of tests and measurements are done. First the electronic boards are checked separately, then the modulates which are built from them are tested separately, and finally a lot of tests are conducted on the assembled system. During these test a lot of data is acquired from the product, but – especially at the final testing of the product – the data acquisition could be difficult, because …”


Szigeti GYP, Hegyi G, Szasz O (2013) Hyperthermia versus Oncothermia: cellular effects in cancer therapy. Oncothermia Journal 7:377-377

Abstract
Hyperthermia means overheating of the living object completely or partly. Hyperthermia the procedure of raising the temperature of a parts of or the whole body above normal for a defined period of time, is applied alone or as an adjunctive with various established cancer treatment modalities such as radiotherapy and chemotherapy….”


Andocs G, Meggyeshazi N, Okamoto Y, Balogh L, Szasz O (2013) Bystander effect of Oncothermia. Oncothermia Journal 7:378-378

Introduction
Oncothermia (OTM) is an electro-hyperthermia modality, a long time (since 1989) applied method in oncology [1] with great clinical success [2]. OTM changes the paradigm of hyperthermia by targeted microscopic heat liberation at the membrane of the malignant cells. This method creates inhomogeneous heating, microscopic temperature differences far from thermal equilibrium. The tumor destruction efficacy and the role of temperature independent effects of the OTM was proven earlier by laboratory research, and presented elsewhere [3], [4]….”


Kim YH, Ju W, Kim C (2013) Electro-hyperthermia for refractory ovarian cancer patient having bone marrowdepletion as a consequence of long-term chemotherapy: Case report. Oncothermia Journal 7:379-379

Abstract
Modulated electro-hyperthermia is an emerging complementary treatment option for refractory solid tumor. Early experience suggests that it may have advantages over conventional hyperthermia with exceeding efficacy, and less complication. Herein, we describe a case of platinum-resistant, refractory ovarian cancer successfully controlled by the combination of electro-hyperthermia and dose-dense chemotherapy…”


Lee DY, Paik HC, Haam SJ (2013) Hyperthermia in the patients with small cell lung cancer. Oncothermia Journal 7:380-380

Introduction
Small cell lung cancer (SCLC) has more rapid doubling time and earlier development of widespread metastasis than non-small cell lung cancer. SCLC is highly sensitive to initial chemotherapy (CTx) and radiotherapy (RTx) but, recurs or spreads quickly. In addition, the surgical role in SCLC is still insignificant. So, the new treatment modality besides conventional treatments is needed to get a better prognosis. The aim of this study is to evaluate the effectiveness of hyperthermia in SCLC patients. …”


Vokalis I, Kouridakis P, Daniilidis L, Natsouki V, Kalyvas S, Maragkos M, Dimitriadis K (2013) Loco regional hyperthermia in Greece: A new treatment modality for treating deep seated tumors. Two years clinical experience from Thessaloniki hyperthermia’s – Oncology operation center – New challegnes. Oncothermia Journal 7:381-381

“1. Central nervous system tumors
3 Man with gliomas an 1 man with astrocytoma. We noticed general improvement as regarding to their performance status and reduction of their tumor mass in routine radiologic tests.
2. Head and neck-oral cavity
1 Man suffering of tongue cancer who received 12 trials of local deep-heat (HT) treatment having received chemo-radiotherapy before. This men developed progressive, disease with lung metastases in the end of the treatment…”


Leckler J (2013) Oncotherm Group Marketing & Sales Strategy. Oncothermia Journal 7:382-382

Sales organization
Organization and coordination/support:
Oncotherm GmbH, Germany
Freelancer in Germany:
The Pockwood Corporation …”


Acs B (2013) Oncotherm products overview. Oncothermia Journal 7:383-383

“Main products
Booster
This product is new kind of innovations in the field of complementary cancer treatment. Its use enhances the effects chemo- and/or radiotherapies, as well as applicable for drug-targeting and personalization of any other medications, irrespective its i. v, oral, injection or other introduction. …”


Oncothermia.ru (2013) EHY-2000 standard treatment zones. Oncothermia Journal 7:384-384

“EHY200 Standard Treatment Zones
© Galenic Research Institute, 2010 …”


Oncothermia.ru (2013) Summary Guidelines. Oncothermia Journal 7:385-385

Summary of oncothermia application
Applicator
Applicator size should match the application gene and tumor size….”


WFCMS (2013) Speciality Committee WFCMS. Oncothermia Journal 7:386-386

“World Federation of Chinese Medicine Societies (WFCMS) is an international academic organization voluntarily formed by group members in the world of Traditional Chinese and Natural Medicine. Currently, WFCMS has 220 society members in 58 countries and regions….”


Oncotherm (2013) Welcome poster. Oncothermia Journal 7:387-387

“Dear Collegues, Dear Members of ICHS, Dear Oncotherm-users,
Hyperthermia started to be an integrative part of the onco-therapies. Ours Society is one of the oldest in this field. ICHS from its establishing  represented the best traditions of the oncological hyperthermia, uniting the best national and international efforts to accept widely this complementary treatment….”


Osmanoglu Hospital (2013) Oncology Center Istanbul. Oncothermia Journal 7:388-388

“    -     Cancer Coaching

  • Cancer Prevention
  • Conventional Chemotherapy
  • Metronomic Therapy
  • Insulin Potentiation Therapy
  • Hyperthermia …”


Seong GM (2013) A case of clinically complete remission of lung with hyperthermia and concurrent 5th-line chemotherapy in a disseminated NSCLC patient. Oncothermia Journal 7:389-389

Backgrounds
Lung cancer is the leading cause of cancer death worldwide. With combination chemotherapy, the median survival is 8-10 months. Besides chemotherapy, various modalities have been evaluated to get better survival. Hyperthermia is a new therapeutic approach and has synergistic effect with chemotherapy to control the disease and to improve the survival….”


 

Oncotherm